Please see the serious Warnings and Precautions associated with IMFINZI.
Safety and tolerability profile for IMFINZI + EP
Adverse reactions were similar with IMFINZI + EP and EP alone and consistent with the safety profiles for IMFINZI and EP1
Adverse reactions occurring in ≥10% of patients in the CASPIAN study1
- Incidence of Grade 3 or 4 adverse events were comparable between IMFINZI + EP (62%) and EP alone (62%)1
Early identification and intervention may help manage many imAEs2
- imAEs of any grade, regardless of cause, were reported in 20% of patients treated with IMFINZI + EP and 3% of patients treated with EP alone1
imAEs=immune-mediated adverse events.
References: 1. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929-1939. 2. Daniels GA, Guerrera AD, Katz D, Viets-Upchurch J. Challenge of immune-mediated adverse reactions in the emergency department. Emerg Med J. 2019;36(6):369-377.3. Paz-Ares LG, Dvorkin M, Chen Y, et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC: updated results from the phase III CASPIAN study. J Clin Oncol. 2020;38(15 suppl). Published online May 25, 2020. doi:10.1200/JCO.2020.38.15_suppl.9002.